[Optimization of the treatment and prevention of thrombus formation in arterial hypertension].
Patients with hypertension and ischemic heart disease develop oftener life threatening thromboembolic complications (ischemic stroke, myocardial infarction), which are conditioned by disorders in the system of blood hemostasis. Along with this, laboratory tests used in medicine are rather variable and not considered to assess risk factor and optimize the treatment individually. In the end of the last century we have developed a laboratory technology called "Co-aguloscop-TC" (the patent of Ukraine), which allows registering in blood 36 parameters of coagulation cascade and calculate two integral parameters which we have named modules of coagulation (MC) and fibrinolysis (MF). As these modules, especially MC reflect the character and degree (from 1 to X) of disorders of coagulation potential, in last studies these modules were used to identify intensity of hypercoagulation as the predictor of thrombus formation and detection of a hemostatic risk factor and calculation of individual doses of some antiaggregants. This article presents results of continuous monitoring (2-6 months) of parameters of blood hemostatic balance in two outpatients with stage II arterial hypertension. Obtained data showed that antiaggregants should be prescribed only after revealing hypercoagulation signs in individual doses depending on the severity of the MC and weight of a patient. At presence of a high risk factor relevant to the VI-VIII degree of hypercoagulation (the thrombosis develops at IX-X degree) it is necessary to use hypotension and antiatherogenic therapy together with parenteral use of antiaggregants (acelisinum, aspisolum) one time per day during 4-6 days).
Tolstopiatov
S M
SM
Naumenko
L E
LE
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D010975:Platelet Aggregation Inhibitors